That's what Bloomberg is reporting. Meanwhile, the Wall Street Journal reported that GlaxoSmithKline (NYSE:GSK) has expressed interest in the recent past, and that J&J (NYSE:JNJ) might get involved as well. If a deal goes through, no matter who ends up making it, it'll be a lot more expensive than it looked like at first.
But isn't that ever the way in M&A? The problem is, everyone except the buyer has a great interest in seeing things go off at the highest possible price.